<DOC>
	<DOCNO>NCT02364596</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity single vaccination investigational vaccine Staphylococcus aureus ( SA4Ag ) healthy adult age 18 &lt; 65 year .</brief_summary>
	<brief_title>Evaluation Single Vaccination With 4-Antigen Staphylococcus Aureus Vaccine ( SA4Ag ) Healthy Adults Aged 18 &lt; 65 Years</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document ( ICD ) indicate subject inform pertinent aspect study . 2 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure , include daily completion ediary 10 day study vaccination . 3 . Healthy male female subject , age 18 &lt; 65 year enrollment , determine medical history , physical examination , clinical judgment investigator eligible study . Subjects preexist chronic medical condition determine stable may include . 4 . Male female subject childbearing potential risk pregnancy must agree use highly effective method contraception throughout study . 5 . Subject must able contact telephone study participation . 1 . Unstable chronic medical condition disease require significant change therapya hospitalization worsen disease within 3 month receipt investigational product . 2 . Serious chronic medical disorder include metastatic malignancy , severe chronic obstructive pulmonary disease ( COPD ) require supplemental oxygen , endstage renal disease without dialysis , clinically unstable cardiac disease , disorder investigator 's opinion precludes subject participate study . 3 . Congenital acquire immunodeficiency disorder , rheumatologic disorder , illness require chronic treatment know immunosuppressant medication , include monoclonal antibody , within year prior enrollment use systemic corticosteroid ( equivalent â‰¥10 mg/day prednisone ) &gt; 14 day within 30 day prior study enrollment . 4 . History leukemia , lymphoma , underlie bone marrow disorder ( eg , myelodysplasia , myeloma , myeloproliferative disorder ) history bone marrow transplant . 5 . Malignancy require treatment chemotherapy , immunotherapy , radiation therapy , antineoplastic target therapy within 24 month prior study enrollment . 6 . Any infection proven suspect caused S. aureus within 6 month precede study vaccination . 7 . Previous administration S. aureus vaccine S. aureus/Candida vaccine . 8 . Any contraindication vaccination vaccine component , include previous anaphylactic reaction vaccine vaccinerelated component . 9 . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . 10 . Donation blood volume 250 mL great ( exclude protocolrequired blood collection ) donation plasma within 3 month prior enrollment conclusion study . 11 . Receipt blood product immunoglobulin ( include monoclonal antibody ) within 6 month enrollment anticipate conclusion subject 's participation . 12 . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised investigator , subject Pfizer employee directly involve conduct study . 13 . Participation study involve investigational drug ( ) ( Phases 14 ) within 30 day current study begin and/or study participation . Participation observational study permit . 14 . Pregnant female subject ; breastfeed female subject ; male subject partner currently pregnant ; male female subject childbearing potential risk pregnancy unwilling unable use highly effective method contraception outline protocol duration study . 15 . Residence nursing home longterm care facility requirement semiskilled nursing care . An ambulatory subject resident retirement home village eligible trial . 16 . Subjects know active disease human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , and/or hepatitis C virus ( HCV ) . 17 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Staphylococcus aureus vaccine</keyword>
	<keyword>Staphylococcal infection</keyword>
</DOC>